Agendia, Daiichi Sankyo collaborate on oncology drug development
Under the deal, Agendia’s oncology biomarker technology will be used in the evaluation of new pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials. Agendia president and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.